Physician profile
Robert Tae Ha
NPI 1750302188
$16,197.44
in general payments reported to CMS, 2019-2025
50 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,291 · 2020: $2,246 · 2021: $2,776 · 2022: $1,911 · 2023: $1,730 · 2024: $1,692 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,355 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $552 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,355.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $552.03 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,111.47 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,369.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,204.36 | 2019-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $1,118.42 | 2021-2023 | |
| Abbvie INC. | $1,030.60 | 2019-2025 | |
| Lilly USA, LLC | $941.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $864.72 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $730.20 | 2019-2025 | Veozah |
| Pfizer INC. | $693.05 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $614.39 | 2024-2025 | Zenpep |
| Optos, INC. | $602.34 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $525.74 | 2019-2022 | |
| Allergan, INC. | $492.75 | 2019-2020 | |
| Gilead Sciences, INC. | $465.53 | 2019-2023 | Vemlidy |
| Dexcom, INC. | $273.85 | 2021-2024 | Dexcom G6 Transmitter |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$95,085.44 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.